Electronic Supplementary Material (ESI) for ChemComm. This journal is © The Royal Society of Chemistry 2022

Oxime Ester-Enabled Anti-Markovnikov Hydrosilylation of Alkenes

Guo Shen, [†] Shaomin Fu, [†]* Bo Liu. [†]*

[†] Key Laboratory of Green Chemistry & Technology of Ministry of Education, College of Chemistry, Sichuan University, Chengdu 610064, China

Correspondence to:

Shaomin Fu, Email: <u>fsm09@aliyun.com;</u>

Bo Liu, Email: <u>chembliu@scu.edu.cn</u>

Supporting Information

Table of Contents

1. General Information	1
2. Syntheses of Initiators and Substrates	2
3. Optimization of Reaction Conditions.	11
4. General Procedures for Syntheses of Alkyl Silanes	12
Gram-Scale Reaction	27
5. Tolerance of Internal Olefins.	28
6. Mechanistic Study	28
7. The Ranational for Both Carbon Radical and Benzoate Radical Interact v	with
Silane via Hydrogen Abstract to Achieve Silyl Radical.	30
8. The Rational for Selecting (TMS) ₃ SiH as Silane for Condition Optimizat	tion.
	31
9. The Rational for Excellent Chemoselectivity of γ -Cyanoalkyl Radical wi	ith
Silane and Alkene.	31
10. Reference	32
11. NMR Spectra	33

1. General Information

All reactions were performed under an argon atmosphere with dry solvents under anhydrous conditions, unless otherwise stated. 1,4-dioxane was distilled from sodium under argon; PhMe and DCM were distilled from calcium hydride under argon; MeOH was distilled from magnesium and iodine under argon; THF was distilled firstly from sodium and then from LiAlH₄ under argon. Unless otherwise noted, all the other chemicals were purchased commercially and used without further purification. Column chromatography was performed using silica gel (200-300 mesh). Thin layer chromatography (TLC) was used for monitoring reactions and visualized by a UV lamp (254 nm and 365 nm), I₂ and developing the plates with PMA or CAM. ¹H and ¹³C NMR were recorded on Bruker DRX-400 NMR spectrometer with TMS as the internal standard and were calibrated using residual undeuterated solvent as an internal reference (CDCl₃: 1 H NMR = 7.26 ppm, 13 C NMR = 77.16 ppm). Abbreviations in ¹H NMR data are illustrated as follows: s = singlet, d = doublet, t = bab data are illustrated as follows: <math>s = singlet, d = doublet, t = bab data are illustrated as follows: <math>s = singlet, d = doublet, t = bab data are illustrated as follows: <math>s = singlet, d = doublet, t = bab data are illustrated as follows: <math>s = singlet, d = doublet, t = bab data are illustrated as follows: <math>s = singlet, d = doublet, t = bab data are illustrated as follows: <math>s = singlet, d = doublet, t = bab data are illustrated as follows: <math>s = singlet, d = doublet, t = bab data are illustrated as follows: <math>s = singlet, d = doublet, t = bab data are illustrated as follows: <math>s = singlet, d = doublet, t = bab data are illustrated as follows: <math>s = singlet, d = doublet, t = bab data are illustrated as follows: <math>s = singlet, d = doublet, t = bab data are illustrated as follows: <math>s = singlet, d = doublet, t = bab data are illustrated as follows: <math>s = singlet, d = doublet, s = singlet, s = singlet, d = doublet, s = singlet, d = doublet, s = singlet, s = singlet, d = doublet, s = singlet, triplet, dd = doublet of doublet, ddd = doublet of doublet of doublet, dt = doublet of triplet, td = triplet of doublet, tdd = triplet of doublet of doublet, m = multiplet, br = broad. Coupling constants (J) are reported in Hertz (Hz). High resolution mass spectra (HRMS) were recorded by using Thermo Scientific Q Exactive hybrid quadrupole-Orbitrap mass spectrometer (Q-exactive orbitrap) and SCIEX QTOF. Gas chromatography mass spectrometry (GC-MS) were recorded by using Shimadzu GCMS-QP2010Plus and Agilent 7890B (GC system) Agilent 5977 MSD. Infrared (IR) spectra were recorded on a BRUKER TENSOR II IR spectrophotometer device and were reported in wavenumbers (cm⁻¹).

2. Syntheses of Initiators and Substrates

The initiators I-VI were prepared according to the procedures described before¹.

Synthesis of oxetan-3-yl undec-10-enoate (1e)

To a refluxing solution of DCC (2.2670 g, 11 mmol, 1.1 equiv.) and DMAP (244.3 mg, 2 mmol, 0.2 equiv.) in CH₂Cl₂ (10 mL) was added allyl acetic acid (983.3 mg, 10 mmol, 1 equiv.) and methylparaben (1.8258 g, 12 mmol, 1.2 equiv.) in DCM (3 mL) dropwise. Then the reaction was stirred at room temperature for 34 h. The mixture was concentrated, and purified by flash chromatography (EA/PE =1/3) to give the desired product (1.9852 g, 86%, pink solid).



Rf = 0.5-0.6 (EA/PE = 1:5; UV & anisaldehyde)

¹**H NMR** (400 MHz, CDCl₃) δ 8.06 (d, *J* = 8.6 Hz, 2H), 7.16 (d, *J* = 8.4 Hz, 2H), 5.90 (ddt, *J* = 16.8, 10.1, 6.4 Hz, 1H), 5.27 – 5.04 (m, 2H), 3.91 (s, 3H), 2.69 (t, *J* = 7.4 Hz, 2H), 2.51 (q, *J* = 7.1 Hz, 2H); ¹³**C NMR** (101 MHz, CDCl₃) δ 171.12, 166.46, 154.48, 136.26, 131.30, 127.82, 121.73, 116.24, 52.33, 33.76, 28.90. **IR** (ATR) 2953, 1761, 1723, 1642, 1436, 1278, 1203, 509 cm⁻¹. **HRMS** (**ESI**) **m/z:** [M+H]⁺ calcd for C₁₃H₁₅O₄: 235.0965; found: 235.0962. **m.p.**: 28.4-29.4 °C.

undec-10-enoic acid (C)



To a dried flask equipped with carboxylic acid **A** (20.2 mL, 100 mmol, 1 equiv.) was added thionyl chloride **B** (11.2 mL, 130 mmol, 1.3 equiv.) dropwise in an icewater bath. The reaction was stirred at 80 °C for 5 h, and concentrated under reduced pressure to obtain the crude acyl chloride **C** which was used in the next step without further purification.

Synthesis of oxetan-3-yl undec-10-enoate (1q)



To a solution of alcohol **D** (695.6 mg, 10 mmol, 1 equiv.) and Et₃N (2.8 mL, 20 mmol, 2 equiv.) in DCM (20 mL) was added acyl chloride **C** (3.6 mL, 13 mmol, 1.3 equiv.) in an ice-water bar. The reaction was stirred at 0 °C for 10 min. Then the reaction was warmed to room temperature and stirred overnight. The resulting mixture was quenched by saturated NaHCO₃ solution and extracted with DCM (30 mL×5). The combined organic layer was dried over anhydrous Na₂SO₄, filtrated, and concentrated under reduced pressure. The residue was purified by flash column chromatography (EA/PE = 1/5) to afford the alkene (1.4395 g, 64%, colorless oil).

Rf = 0.6-0.7 (EA/PE = 1:5; I₂, anisaldehyde & PMA).

¹**H NMR** (400 MHz, CDCl₃) δ 5.80 (ddt, *J* = 16.9, 10.2, 6.7 Hz, 1H), 5.42 (tt, *J* = 6.4, 5.3 Hz, 1H), 5.02 – 4.90 (m, 2H), 4.88 (ddd, *J* = 7.4, 6.4, 1.0 Hz, 2H), 4.62 (ddd, *J* = 7.4, 5.3, 1.0 Hz, 2H), 2.34 (t, *J* = 7.5 Hz, 2H), 2.07 – 1.99 (m, 2H), 1.63 (q, *J* = 7.6 Hz, 2H), 1.40 – 1.26 (m, 10H); ¹³**C NMR** (101 MHz, CDCl₃) δ 173.24, 139.27, 114.30, 77.77, 67.81, 34.08, 33.90, 29.38, 29.28, 29.18, 29.16, 29.00, 24.92. **IR** (ATR) 2926, 2855, 1739, 1640, 1237, 1165, 1121, 1047 cm⁻¹. **HRMS** (**APCI**) **m/z:** [M-H]⁻ calcd for C₁₄H₂₃O₃: 239.1653; found: 239.1656.

2-methoxyphenyl undec-10-enoate (1r)



To a solution of methyl guaiacol (1.2773 g, 10 mmol, 1 equiv.) and Et_3N (2.8 mL, 20 mmol, 2 equiv.) in DCM (20 mL) was added acyl chloride C (3.6 mL, 13 mmol, 1.3 equiv.) in an ice-water bar. The reaction was stirred at 0 °C for 10 min. Then the

reaction was warmed to room temperature and stirred overnight. The mixture was quenched by saturated NaHCO₃ solution and extracted with DCM (30 mL \times 5). The combined organic layer was dried over anhydrous Na₂SO₄, filtrated, and concentrated under reduced pressure. The residue was purified by flash column chromatography (EA/PE= 1/10) to afford the alkene (2.1187 g, 71%, yellow oil).

Rf = 0.6-0.7 (EA/PE = 1:10; UV & anisaldehyde).

¹**H NMR** (400 MHz, CDCl₃) δ 7.19 (ddd, J = 8.2, 7.3, 1.7 Hz, 1H), 7.02 (dd, J = 7.8, 1.8 Hz, 1H), 6.99 – 6.90 (m, 2H), 5.82 (ddt, J = 16.9, 10.2, 6.7 Hz, 1H), 5.05 – 4.90 (m, 2H), 3.82 (s, 3H), 2.58 (t, J = 7.5 Hz, 2H), 2.09 – 2.00 (m, 2H), 1.82 – 1.72 (m, 2H), 1.49 – 1.29 (m, 10H); ¹³**C NMR** (101 MHz, CDCl₃) δ 172.03, 151.29, 140.00, 139.30, 126.87, 122.97, 120.87, 114.29, 112.52, 55.93, 34.18, 33.92, 29.47, 29.36, 29.20, 29.17, 29.04, 25.17. **IR** (ATR) 2926, 2854, 1763, 1640, 1280, 1258, 1027, 748 cm⁻¹. **HRMS (APCI) m/z:** [M+H]⁺ calcd for C₁₈H₂₇O₃: 291.1955; found: 291.1952.

Synthesis of methyl 3-methoxy-4-(undec-10-enoyloxy)benzoate (1s)



To a solution of methyl vanillate (10 mmol) in DCM (20 mL) and Et₃N (2.8 mL, 20 mmol, 2 equiv.) was added acyl chloride **C** (3.6 mL, 13 mmol, 1.3 equiv.) in an ice-water bar. The reaction was stirred at 0 °C for 10 min. Then the reaction was warmed to room temperature and stirred overnight. The mixture was quenched by saturated NaHCO₃ solution and extracted with DCM (30 mL×5). The combined organic layer was dried over anhydrous Na₂SO₄, filtrated, and concentrated under reduced pressure. The residue was purified by flash column chromatography to afford the alkene (2.8693 g, 82%, dark brown oil).

Rf = 0.7-0.8 (EA/PE = 1:5; UV & I₂ & anisaldehyde).

¹**H** NMR (400 MHz, CDCl₃) δ 7.68 – 7.61 (m, 2H), 7.08 (d, J = 8.1 Hz, 1H), 5.81 (ddt, J = 16.9, 10.2, 6.7 Hz, 1H), 5.03 – 4.88 (m, 2H), 3.91 (s, 3H), 3.87 (s, 3H), 2.58 (t, J = 7.4 Hz, 2H), 2.09 – 1.98 (m, 2H), 1.83 – 1.71 (m, 2H), 1.48 – 1.25 (m, 10H);

¹³**C NMR** (101 MHz, CDCl₃) δ 171.46, 166.52, 151.20, 143.87, 139.26, 128.80, 122.91, 122.72, 114.29, 113.50, 56.14, 52.37, 34.11, 33.89, 29.43, 29.32, 29.17, 29.11, 29.01, 25.05. **IR** (ATR) 2927, 2854, 1767, 1724, 1640, 1603, 1243, 1198, 1171, 1117, 1034, 761 cm⁻¹. **HRMS (APCI) m/z**: [M+Na]⁺ calcd for C₂₀H₂₉O₅: 371.1829; found: 371.1834.

Synthesis of N-(2-(1H-indol-2-yl)ethyl)-O-(undec-10-enoyl)hydroxylamine (1t)



To a dried flask quipped with a stir bar, was added tryptamine (480.7 mg, 3 mmol, 1 equiv.). The flask was then evacuated and back-filled with Ar for 3 times. Then DCM (10 mL) and Et₃N (1.4 mL, 10 mmol, 2 equiv.) was added. The reaction was cooled to an ice-water bath and added acyl chloride C (1.2 mL, 4.5 mmol, 1.5 equiv.) dropwise. The reaction mixture was stirred overnight. The resulting solution was quenched by saturated NaHCO₃ solution (20 mL) and extracted with DCM (30 mL × 5). The combined organic layer was dried over anhydrous Na₂SO₄, filtrated, and concentrated under reduced pressure. The residue was purified by flash column chromatography (EA/PE = 1/1 to EA to MeOH/DCM = 1/10) to afford the desired alkene (347.6 mg, 35%, purple solid).

Rf = 0.5-0.6 (EA/PE = 1:1; UV & anisaldehyde).

¹**H NMR** (400 MHz, CDCl₃) δ 8.08 (s, 1H), 7.61 (d, J = 7.9 Hz, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.21 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 7.16 – 7.10 (m, 1H), 7.04 (d, J = 2.3 Hz, 1H), 5.81 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H), 5.48 (s, 1H), 5.03 – 4.89 (m, 2H), 3.61 (q, J = 6.5 Hz, 2H), 2.98 (t, J = 6.7 Hz, 2H), 2.13 – 2.07 (m, 2H), 2.03 (qt, J = 6.8, 1.4 Hz, 2H), 1.56 (d, J = 7.1 Hz, 2H), 1.26 (s, 10H); ¹³C NMR (101 MHz, CDCl₃) δ 173.41, 139.33, 136.57, 127.50, 122.32, 122.17, 119.60, 118.85, 114.29, 113.13, 111.42, 39.84, 36.97, 33.90, 29.42, 29.40, 29.38, 29.18, 29.01, 25.86, 25.48. IR (ATR) 3396, 3271, 3077, 2923, 2852, 1636, 1526, 1456, 1434, 1341, 1226, 1097, 993, 909, 803, 740, 584,

557, 483 cm⁻¹. **HRMS (APCI) m/z**: [M+H]⁺ calcd for C₂₁H₃₁N₂O: 327.2431; found: 327.2433. **m.p.**: 85.6-86.6 °C.

(1*r*,3*r*,5*r*,7*r*)-adamantan-2-yl acrylate (1ag)

To a dried flask was equipped with a stir bar and 2-adamantanol (1.5344 g, 10 mmol, 1 equiv.). The flask was then evacuated and back-filled with Ar for 3 times. DCM (14 mL) and Et₃N (2.1 mL, 15 mmol, 1.5 equiv.) was added. The reaction was cooled in an ice-water bath and added acryloyl chloride (809 μ L, 10 mmol, 1 equiv.) dropwise. The resulting mixture was stirred overnight, and then concentrated under reduced pressure. The residue was purified by flash column chromatography (EA/PE = 1/10) to afford the alkene (1.2069 g, 79%, white solid).

Rf = 0.8-0.9 (EA/PE = 1:10; I_2 & anisaldehyde).

¹**H NMR** (400 MHz, CDCl₃) δ 6.40 (dd, J = 17.3, 1.6 Hz, 1H), 6.15 (dd, J = 17.3, 10.4 Hz, 1H), 5.81 (dd, J = 10.4, 1.6 Hz, 1H), 5.04 – 4.95 (m, 1H), 2.04 (dt, J = 10.2, 3.0 Hz, 5H), 1.92 – 1.71 (m, 9H), 1.57 (ddt, J = 10.9, 3.1, 1.5 Hz, 2H); ¹³**C NMR** (101 MHz, CDCl₃) δ 165.74, 130.14, 129.49, 77.26, 37.52, 36.47, 32.01, 31.95, 27.39, 27.14. **IR** (ATR) 2908, 2854, 1635, 1449, 1406, 1340, 1296, 1272, 1192, 1098, 1044, 989, 903, 811 cm⁻¹. **HRMS (ESI) m/z**: [M+H]⁺ calcd for C₁₃H₁₉O₂: 207.1380; found: 207.1379. **m.p.**: 62.3-63.1 °C.

(8*R*,9*S*,13*S*,14*S*)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6Hcyclopenta[a]phenanthren-3-yl hept-6-enoate (1ak)

To a dried flask was added the carboxylic acid (1.1mL, 7.5 mmol, 1.5 equiv.), followed by addition of thionyl chloride (0.7 mL, 9 mmol, 1.8 equiv.) dropwise in an ice-water bar. After refluxing the above solution at 80 °C for 3 h, extra thionyl chloride was removed under reduced pressure. The crude acyl chloride was used in the next step without further purification.

To a solution of cholesterol (1.3526 g, 5 mmol, 1 equiv.) in DCM (10 mL) was added acyl chloride and Et_3N (1.4 mL, 10 mmol, 2 equiv.) in an ice-water bar. The reaction was stirred at 0 °C for 10 min. Then the reaction was warmed to room

temperature and stirred for another 11 h. The mixture was poured into saturated NaHCO₃ solution (20 mL) and extracted with DCM (30 mL×5). The combined organic layer was dried over anhydrous Na₂SO₄, filtrated, and concentrated under reduced pressure. The residue was purified by flash column chromatography (EA/PE = 1/5) to afford the alkene (1.7500 g, 95%, light yellow oil).



Rf = 0.5-0.6 (EA/PE = 1:5; I_2 & anisaldehyde).

¹**H NMR** (400 MHz, CDCl₃) δ 7.26 (d, *J* = 8.5 Hz, 1H), 6.87 – 6.77 (m, 2H), 5.81 (ddt, *J* = 16.9, 10.2, 6.6 Hz, 1H), 5.07 – 4.92 (m, 2H), 2.89 (dd, *J* = 8.2, 3.5 Hz, 2H), 2.56 – 2.51 (m, 2H), 2.51 – 2.44 (m, 1H), 2.42 – 2.35 (m, 1H), 2.30 – 2.22 (m, 1H), 2.16 – 2.07 (m, 3H), 2.05 – 1.92 (m, 3H), 1.76 (p, *J* = 7.5 Hz, 2H), 1.67 – 1.38 (m, 9H); ¹³**C NMR** (101 MHz, CDCl₃) δ 220.60, 220.55, 172.33, 172.31, 148.61, 138.27, 137.91, 137.23, 126.32, 121.55, 118.74, 114.82, 50.38, 47.88, 44.11, 37.98, 35.81, 34.17, 33.32, 31.54, 29.37, 28.27, 26.32, 25.73, 24.38, 21.55, 13.80. **IR** (ATR) 2930, 2861, 1740, 1640, 1494, 1208, 1151, 1054, 1007, 912, 820 cm⁻¹. **HRMS (APCI) m/z**: [M+H]⁺ calcd for C₂₅H₃₃O₃: 381.2424; found: 381.2428.

(3*S*,8*S*,9*S*,10*R*,13*R*,14*S*,17*R*)-10,13-dimethyl-17-((*R*)-6-methylheptan-2-yl)-

2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl pent-4-enoate (1al)

To a dried flask was added carboxylic acid (1.5018 g, 15 mmol, 1.5 equiv.), followed by addition of thionyl chloride (2.2 mL, 30 mmol, 3 equiv.) dropwise in an ice-water bar. The reaction was stirred at 80 °C for 5 h, then the resulting mixture was concentrated under reduced pressure to remove thionyl chloride. The crude acyl chloride was used in the next step without further purification.

To a solution of cholesterol (3.8666 g, 10 mmol, 1 equiv.) in DCM (10 mL) was added above acyl chloride and Et₃N (5.6 mL, 40 mL, 4 equiv.) in an ice-water bar. The reaction was stirred at this temperature for 10 min. Then the reaction was warmed to room temperature and stirred for another 11 h. The mixture was quenched by

saturated NaHCO₃ solution (20 mL) and extracted with DCM (30 mL×5). The combined organic layer was dried over anhydrous Na₂SO₄, filtrated, and concentrated under reduced pressure. The residue was purified by flash column chromatography (EA/PE= 1/50 to 1/30) to afford the alkene (966.0 mg, 21%, white solid).



Rf = 0.5-0.6 (EA/PE = 1:5; I_2 & anisaldehyde).

¹**H NMR** (400 MHz, CDCl₃) δ 5.90 – 5.73 (m, 1H), 5.37 (dq, J = 5.0, 1.7 Hz, 1H), 5.13 – 4.95 (m, 2H), 4.69 – 4.56 (m, 1H), 2.37 (d, J = 2.9 Hz, 3H), 2.34 – 2.28 (m, 2H), 1.99 (ddt, J = 20.0, 16.9, 4.3 Hz, 2H), 1.84 (dtd, J = 12.8, 6.3, 5.9, 3.4 Hz, 3H), 1.62 – 1.42 (m, 8H), 1.39 – 1.23 (m, 5H), 1.20 – 1.05 (m, 7H), 1.02 (d, J = 2.8 Hz, 4H), 0.98 – 0.95 (m, 1H), 0.91 (d, J = 6.6 Hz, 3H), 0.86 (dd, J = 6.6, 1.8 Hz, 6H), 0.68 (s, 3H); ¹³**C NMR** (101 MHz, CDCl₃) δ 172.63, 139.82, 136.92, 122.79, 115.56, 74.07, 56.84, 56.29, 50.18, 42.46, 39.88, 39.67, 38.30, 37.14, 36.74, 36.33, 35.94, 34.04, 32.06, 32.01, 29.14, 28.38, 28.17, 27.96, 24.43, 23.98, 22.97, 22.71, 21.18, 19.47, 18.86, 12.01. **IR** (ATR) 2942, 2868, 1734, 1643, 1466, 1378, 1272, 1175, 1000, 914, 752 cm⁻¹. **HRMS (ESI) m/z**: [M+Na]⁺ calcd for C₃₂H₅₂NaO₂: 491.3860; found: 491.3865. **m.p.**: 70.1-71.1 °C.

4-phenylbutan-2-one O-benzoyl oxime (VII)

NH₂OH•HCl (6 mmol, 2 equiv.) and acetone (3 mmol, 1 equiv.) in pyridine (3 mL) was stirred 4 hours. the reaction mixture was poured into saturated NaHCO₃ solution (60 mL). The resulting mixture was extracted with EA (30 mL \times 5). The organic layer was dried over anhydrous Na₂SO₄. The solvent was removed in vacuo and the crude oxime was obtained.

To a solution of the crude oxime (1.0 equiv.) in CH_2Cl_2 (2.0 mL/mmol) were added triethylamine (6 mmol, 2 equiv.) and benzoyl chloride (4.5 mmol, 1.5 equiv.) in an ice-water bath. After stirring for 14 h, the reaction mixture was quenched by saturated NaHCO₃ solution (10 mL). The resulting mixture was extracted with DCM (10 mL \times 5). The organic layer was dried over anhydrous Na₂SO₄. The solvent was removed in vacuo and the residue was purified by column chromatography (EA/PE = 1/5) to obtain oxime ester **VII** (644.3 mg, 73%, white solid).



¹**H NMR** (400 MHz, CDCl₃) δ 8.12 – 8.06 (m, 2H), 7.59 (ddt, J = 8.0, 6.9, 1.4 Hz, 1H), 7.51 – 7.44 (m, 2H), 7.34 – 7.29 (m, 2H), 7.26 – 7.19 (m, 3H), 3.01 – 2.93 (m, 2H), 2.80 – 2.71 (m, 2H), 2.14 (s, 3H); ¹³**C NMR** (101 MHz, CDCl₃) δ 166.89, 164.08, 140.62, 133.37, 129.74, 129.44, 128.75, 128.67, 128.51, 126.51, 37.95, 32.78, 16.13. **HRMS** (**ESI**) **m/z**: [M+Na]⁺ calcd for C₁₇H₁₇NNaO₂: 290.1151; found: 290.1149.

heptan-2-one O-benzoyl oxime (VIII)

NH₂OH•HCl (6 mmol, 2 equiv.) and acetone (3 mmol, 1 equiv.) in pyridine (3 mL) was stirred 4 hours. the reaction mixture was poured into saturated NaHCO₃ solution (60 mL). The resulting mixture was extracted with EA (30 mL \times 5). The organic layer was dried over anhydrous Na₂SO₄. The solvent was removed in vacuo and the crude oxime was obtained.

To a solution of the crude oxime (1.0 equiv.) in CH_2Cl_2 (2.0 mL/mmol) were added triethylamine (6 mmol, 2 equiv.) and benzoyl chloride (4.5 mmol, 1.5 equiv.) in an ice-water bath. After stirring for 14 h, the reaction mixture was quenched by saturated NaHCO₃ solution (10 mL). The resulting mixture was extracted with DCM (10 mL × 5). The organic layer was dried over anhydrous Na₂SO₄. The solvent was removed in vacuo and the residue was purified by column chromatography (EA/PE = 1/5) to obtain oxime ester **VIII** (155.2 mg, 21%, colorless oil).



¹**H** NMR (400 MHz, CDCl₃) δ 8.11 – 8.01 (m, 2H), 7.62 – 7.55 (m, 1H), 7.47 (td, J = 7.7, 3.1 Hz, 2H), 2.57 – 2.49 (m, 1H), 2.46 – 2.38 (m, 0H), 2.11 (d, J = 1.8 Hz, 3H), 1.68 – 1.58 (m, 2H), 1.42 – 1.31 (m, J = 3.9, 3.3 Hz, 4H), 0.91 (h, J = 2.5 Hz, 3H).;

¹³C NMR (101 MHz, CDCl₃) δ 168.41, 167.88, 164.14, 133.30, 133.28, 129.71, 129.68, 129.55, 128.68, 128.64, 35.99, 31.88, 31.55, 31.08, 26.20, 25.67, 22.50, 22.47, 20.43, 15.56, 14.07, 14.01. HRMS (ESI) m/z: [M+Na]⁺ calcd for C₁₄H₁₉NaNO₂: 256.1308; found: 256.1305.

butane-2,3-dione O,O-dibenzoyl dioxime (IX)

To a solution of oxime (1.0 equiv.) in CH₂Cl₂ (2.0 mL/mmol) were added triethylamine (2.4 mL, 17.5 mmol, 3.5 equiv.) and benzoyl chloride (1.5 mL, 12.5 mmol, 2.5 equiv.) in an ice-water bath. After stirring for 22 h, the reaction mixture was quenched by saturated Na₂CO₃ solution (10 mL). The resulting mixture was extracted with DCM (10 mL \times 5). The organic layer was dried over anhydrous Na₂SO₄. The solvent was removed in vacuo and the residue was purified by column chromatography (EA/PE = 1/1) to obtain oxime ester **IX** (852.8 mg, 53%, white solid).



¹**H** NMR (400 MHz, CDCl₃) δ 8.16 – 8.11 (m, 4H), 7.65 (ddt, J = 8.7, 7.0, 1.4 Hz, 2H), 7.54 – 7.49 (m, 4H), 2.52 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 163.13, 161.65, 133.82, 129.84, 128.76, 128.46, 12.18. IR (ATR) 1748, 1599, 1491, 1451, 1367, 1241, 1180, 1148, 1055, 1023, 974, 927, 706, 653 cm⁻¹. HRMS (ESI) m/z: [M+Na]⁺ calcd for C₁₈H₁₆N₂NaO₄: 347.1002; found: 347.0999. **m.p.**: 229.5-230.5 °C.

To a solution of LiAlD₄ (209.9 mg, 5 mmol, 0.5 equiv.) in anhydrous ethyl ether (20 mL) was added Ph₂SiCl₂ (2.1 mL, 10 mmol, 1 equiv.) in an ice-water bar. The reaction was stirred at this temperature for 10 min. Then the reaction was warmed to room temperature and reflux for overnight. The mixture was quenched by ice-water (2 mL), then added 20 mL water and extracted with ethyl ether (30 mL×5). The combined organic layer was dried over anhydrous Na₂SO₄, filtrated, and concentrated under reduced pressure. The residue was purified by flash column chromatography (PE (30-60 °C)) to afford Ph₂SiD₂ (1.2142 g, 64%, D> 99%, colerless oil).

 $\begin{array}{c} \begin{array}{c} \text{LiAID}_4 \text{ (0.5 equiv.)} \\ \hline \text{Ph}_2 \text{SiCI}_2 \end{array} \xrightarrow{\begin{array}{c} \text{LiAID}_4 \text{ (0.5 equiv.)} \\ \hline \text{Ft}_2 \text{O, overnight} \end{array}} Ph_2 \text{SiD}_2 \\ 1.2142 \text{ g, } 64\% \end{array}$

Rf = 0.9-1.0 (PE; UV & I_2).

¹**H NMR** (400 MHz, CDCl₃) δ 7.68 – 7.58 (m, 4H), 7.41 (ddd, J = 14.2, 7.7, 6.2 Hz, 6H); ¹³**C NMR** (101 MHz, CDCl₃) δ 135.84, 131.61, 130.03, 128.28.

3. Optimization of Reaction Conditions.

	H (TMS) ₃ SiH (2.5 equiv.)	<
Pn	↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓] Si(TMS)₃
	1a 60 °C, 48 h, N ₂ 2a	
Entry ^a	variations from the "standard' conditions	Yield [♭]
1	none	98% (94%) ^c
2	initiator II instead of I	98%
3	initiator III instead of I	nr ^d
4	initiator ${f IV}$ instead of ${f I}$	97%
5	initiator ${f V}$ instead of ${f I}$	98%
6	initiator VI instead of I	<5%
7	initiator VII instead of I	5% ^e
8	initiator VIII instead of I	10%
9	initiator IX instead of I	80%
10	1 mol% of initiator I instead of 5 mol%	88%
11	2.0 equiv. of (TMS) ₃ SiH instead of 2.5 equiv.	92%
12	PhSiH₃ instead of (TMS)₃SiH	55%
13	Ph ₂ SiH ₂ instead of (TMS) ₃ SiH	20%
14	Et ₃ SiH instead of (TMS) ₃ SiH	5%
15	(MeO)2MeSiH instead of (TMS)3SiH	6%
16	PhMe instead of 1, 4-dioxane	93%
17	THF instead of 1, 4-dioxane	80%
18	Et ₂ O instead of 1, 4-dioxane	60%
19	Ethyl acetate instead of 1, 4-dioxane	88%
20	MeOH instead of 1, 4-dioxane	80%
21	50 °C instead of 60 °C	93%
22	40 °C instead of 60 °C	85%
23	36 h instead of 48 h	89%



^{*a*} The reaction was performed on a 0.2 mmol scale. ^{*b*} Determined by ¹H NMR integration against an internal standard (3,4-dimethoxy-acetophenone). ^{*c*} Isolated yield. ^{*d*} nr = no reaction. ^{*e*} 95% of starting material is recovered. ^{*f*} 90% of starting material is recovered.

4. General Procedures for Syntheses of Alkyl Silanes





A dried Schlenk tube (10 mL) was charged with a stirring bar, the alkene (1, 35.0 mg, 0.2 mmol, 1 equiv.) and oxime ester (0.9 mg, 0.01 mmol, 5 mol%). The Schlenk tube was then evacuated and back-filled with nitrogen (N₂, 99.999%) for 3 times. Then, fresh-distilled anhydrous 1,4-dioxane (2 mL) and (TMS)₃SiH (153 μ L, 0.5 mmol, 2.5 equiv.) was added via syringe under N₂. The reaction mixture was stirred at 60 °C for 48 h. After completion, the reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to afford the desired alkyl silane products **2**.

N-phenyl-5-(phenylsilyl)pentanamide (3a)



55%; (¹H NMR yield, 3,4-dimethoxyacetophenone was an internal standard); $R_f = 0.4$ - 0.5 (PE/EA = 5:1, UV);

¹**H** NMR (400 MHz, CDCl₃) δ 7.60 – 7.54 (m, 2H), 7.49 (d, J = 8.0 Hz, 2H), 7.42 –

7.28 (m, 5H), 7.18 (s, 1H), 7.10 (t, J = 7.4 Hz, 1H), 4.30 (t, J = 3.7 Hz, 2H), 2.34 (t, J = 7.5 Hz, 2H), 1.80 (p, J = 7.5 Hz, 2H), 1.60 – 1.48 (m, 2H), 1.05 – 0.93 (m, 2H); ¹³C **NMR** (101 MHz, CDCl₃) δ 171.26, 138.04, 135.34, 132.47, 129.76, 129.12, 128.17, 124.35, 119.94, 37.55, 28.76, 24.95, 10.03. **IR** (ATR) 3297, 2925, 2130, 1599, 1542, 1498, 1116, 879, 840, 754, 697, 560 cm⁻¹. **HRMS** (**ESI**) **m/z**: [M+Na]⁺ Calcd for C₁₇H₂₁NNaOSi: 306.1285; found: 306.1282.

4-(1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilan-2-yl)-*N*-phenylbutanamide (2a)



79.6 mg, 94%, white solid; Rf = 0.4-0.5 (EA/PE = 1:5; UV);

¹**H NMR** (400 MHz, CDCl₃) δ 7.54 – 7.44 (m, 2H), 7.30 (t, *J* = 7.8 Hz, 2H), 7.09 (t, *J* = 7.4 Hz, 1H), 2.40 – 2.28 (m, 2H), 1.76 (p, *J* = 7.5 Hz, 2H), 1.55 – 1.43 (m, 2H), 0.86 – 0.74 (m, 2H), 0.15 (s, 27H); ¹³**C NMR** (101 MHz, CDCl₃) δ 171.43, 138.08, 129.09, 124.30, 119.99, 37.58, 30.12, 29.05, 7.52, 1.28. **IR** (ATR) 3288, 2948, 1661 1444, 1302, 830, 690, 623 cm⁻¹. **HRMS** (**APCI**) **m/z**: [M+Na]⁺ calcd for C₂₀H₄₁NNaOSi₄: 446.2157; found: 446.2158. **m.p.**: 116.6-117.5 °C.

3,3-di-tert-butyl-1,1,1,3,3,3-hexamethyl-2-(4-phenylbutyl)-2-(trimethylsilyl)trisilane (2b)



83.3 mg, 99%, colorless oil; Rf = 0.9 - 1.0 (PE; I₂ & PMA);

¹**H NMR** (400 MHz, CDCl₃) δ 7.38 – 7.31 (m, 2H), 7.27 – 7.21 (m, 3H), 2.72 – 2.66 (m, 2H), 1.73 (p, J = 7.4 Hz, 2H), 1.54 – 1.45 (m, 2H), 0.90 – 0.84 (m, 2H), 0.22 (s, 27H); ¹³**C NMR** (101 MHz, CDCl₃) δ 142.82, 128.56, 128.38, 125.70, 36.08, 35.66, 28.99, 7.61, 1.30. IR (ATR) 2948, 1450, 1243, 1029, 831, 744, 691, 622 cm⁻¹. **GC**–**MS** m/z: 380 M⁺, 247 (TMS)₃Si⁺, 133 (Ph(CH₂)₄)⁺.

2-(4-(4-(*tert*-butyl)phenyl)-3-methylbutyl)-1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilane (2c)



57.6 mg, 64%, colorless oil; Rf = 0.9 - 1.0 (PE; I₂ & PMA); ¹H NMR (400 MHz, CDCl₃) δ 7.30 (d, J = 8.0 Hz, 2H), 7.09 (d, J = 7.9 Hz, 2H), 2.49 (d, J = 7.5 Hz, 2H), 1.66 (ddd, J = 14.0, 9.6, 6.1 Hz, 1H), 1.50 – 1.38 (m, 1H), 1.33 (d, J = 0.9 Hz, 9H), 1.16 (tdd, J = 13.1, 8.1, 4.6 Hz, 1H), 0.96 – 0.84 (m, 4H), 0.69 – 0.60 (m, 1H), 0.15 – 0.12 (m, 27H); ¹³C NMR (101 MHz, CDCl₃) δ 148.45, 138.59, 128.91, 125.15, 43.01, 38.81, 35.66, 34.46, 31.59, 19.35, 4.68, 1.27. IR (ATR) 2952, 1460, 830, 744, 685, 622 cm⁻¹. GC–MS m/z: 450 M⁺, 247 (TMS)₃Si⁺, 203 (M-Si(TMS)₃)⁺, 146 (M-Si(TMS)₃-^{*t*}Bu)⁺.

phenyl 5-(1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilan-2-yl)pentanoate (2d)



80.9 mg, 94%, colorless oil; Rf = 0.8 – 0.9 (PE/EA = 20:1; UV, I₂ & PMA);

¹**H NMR** (400 MHz, CDCl₃) δ 7.41 – 7.34 (m, 2H), 7.25 – 7.19 (m, 1H), 7.10 – 7.03 (m, 2H), 2.57 (t, J = 7.5 Hz, 2H), 1.86 – 1.74 (m, 2H), 1.52 (dddd, J = 14.9, 9.0, 6.5, 4.2 Hz, 2H), 0.88 – 0.78 (m, 2H), 0.17 (s, 27H); ¹³**C NMR** (101 MHz, CDCl₃) δ 172.33, 150.91, 129.52, 125.84, 121.72, 34.16, 29.42, 28.91, 7.52, 1.31. **IR** (ATR) 2949, 1761, 1244, 1195, 1163, 1115, 833, 747, 688, 623 cm⁻¹. **HRMS (APCI) m/z**: [M+Na]⁺ calcd for C₂₀H₄₀NaO₂Si₄: 447.1998; found: 447.1997.

methyl 4-((5-(1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilan-2-yl)pentanoyl)oxy)-benzoate (2e)



96.9 mg, 98%, colorless oil; Rf = 0.8 – 0.9 (EA/PE = 1:5; UV, I₂ & PMA);

¹H NMR (400 MHz, CDCl₃) δ 8.08 – 8.03 (m, 2H), 7.18 – 7.12 (m, 2H), 3.91 (s, 3H),
2.58 (t, *J* = 7.5 Hz, 2H), 1.79 (p, *J* = 7.4 Hz, 2H), 1.57 – 1.46 (m, 2H), 0.87 – 0.78 (m,
2H), 0.17 (s, 27H); ¹³C NMR (101 MHz, CDCl₃) δ 171.72, 166.44, 154.55, 131.27,

127.72, 121.71, 52.28, 34.09, 29.27, 28.82, 7.49, 1.27. **IR** (ATR) 2949, 1764, 1726, 1277, 1243, 1203, 1160, 1101, 1017, 970, 829, 764, 687, 623 cm⁻¹. **HRMS (APCI) m/z**: [M+H]⁺ calcd for C₂₂H₄₃O₄Si₄: 483.2233; found: 483.2238.

(*E*)-3,7-dimethylocta-2,6-dien-1-yl 5-(1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl) trisilan-2-yl)pentanoate (2f)



113.1 mg, 100%, colorless oil; Rf = 0.5 - 0.6 (PE/EA = 10:1; I_2 & PMA);

¹**H NMR** (400 MHz, CDCl₃) δ 5.33 (ddq, J = 7.1, 5.7, 1.3 Hz, 1H), 5.08 (tdt, J = 5.8, 3.0, 1.5 Hz, 1H), 4.62 – 4.53 (m, 2H), 2.30 (td, J = 7.7, 3.0 Hz, 2H), 2.14 – 2.01 (m, 4H), 1.72 – 1.56 (m, 11H), 1.46 – 1.36 (m, 2H), 0.82 – 0.71 (m, 2H), 0.15 (s, 27H); ¹³**C NMR** (101 MHz, CDCl₃) δ 173.91, 142.18, 131.91, 123.91, 118.55, 61.37, 39.68, 34.10, 29.47, 28.88, 26.45, 25.82, 17.82, 16.60, 7.39, 1.27. **IR** (ATR) 2948, 1736, 1244, 1180, 982, 831, 748, 687, 623 cm⁻¹. **HRMS** (**APCI**) **m/z**: [M+H]⁺ calcd for C₂₄H₅₃O₂Si₄: 485.3117; found: 485.3121.

naphthalen-2-ylmethyl5-(1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilan-2-yl)pentanoate (2g)



101.6 mg, 100%, colorless oil; Rf = 0.4 - 0.5 (PE/EA = 50:1; UV, I₂ & PMA);

¹**H** NMR (400 MHz, CDCl₃) δ 7.88 – 7.81 (m, 4H), 7.52 – 7.44 (m, 3H), 5.28 (s, 2H), 2.43 – 2.37 (m, 2H), 1.71 (p, *J* = 7.4 Hz, 2H), 1.48 – 1.40 (m, 2H), 0.81 – 0.75 (m, 2H), 0.15 (s, 27H); ¹³**C** NMR (101 MHz, CDCl₃) δ 173.74, 133.63, 133.35, 133.25, 128.52, 128.12, 127.84, 127.50, 126.40, 126.37, 126.06, 66.42, 34.08, 29.42, 28.89, 7.41, 1.27. **IR** (ATR) 2948, 1738, 1244, 1178, 834, 748, 688, 623 cm⁻¹. **HRMS (ESI) m/z**: [M+Na]⁺ calcd for C₂₅H₄₄NaO₂Si₄: 511.2311; found: 511.2306.

1,1,1,3,3,3-hexamethyl-2-(3-phenoxypropyl)-2-(trimethylsilyl)trisilane (2h)



62.7 mg, 90%, colorless oil; Rf = 0.3 - 0.4 (PE/EA = 20:1; I_2 & PMA);

¹**H NMR** (400 MHz, CDCl₃) δ 2.41 (t, *J* = 7.5 Hz, 2H), 2.13 (s, 3H), 1.60 (tt, *J* = 8.3, 6.3 Hz, 2H), 1.38 (dddd, *J* = 13.3, 11.3, 6.5, 3.8 Hz, 2H), 0.79 – 0.70 (m, 2H), 0.14 (s, 27H); ¹³**C NMR** (101 MHz, CDCl₃) δ 209.30, 43.49, 29.99, 28.94, 28.45, 7.59, 1.27. IR (ATR) 2927, 1743, 1452, 1396, 707 cm⁻¹. **GC–MS** m/z: 346 M⁺, 247 (TMS)₃Si⁺, 99 (M-Si(TMS)₃)⁺.

4-(1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilan-2-yl)butan-1-ol (2i)

63.9 mg, 100%, colorless oil; Rf = 0.9 - 1.0 (PE/EA = 1/1; I₂ & PMA); ¹H NMR (400 MHz, CDCl₃) δ 3.63 (t, J = 6.6 Hz, 2H), 1.64 – 1.52 (m, 3H), 1.49 – 1.39 (m, 2H), 0.81 – 0.75 (m, 2H), 0.15 (s, 27H); ¹³C NMR (101 MHz, CDCl₃) δ 62.58, 37.31, 25.38, 7.62, 1.30; IR (ATR) 3325, 2948, 1397, 1244, 622 cm⁻¹. HRMS

(**APCI**) **m/z**: [M+H]⁺ calcd for C₁₃H₃₇NaOSi₄: 321.1916; found: 321.1917.

methyl 4-(4-(1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilan-2-yl)-3methylbutoxy)benzoate (2j)



43.7 mg, 31%, yellow oil; Rf = 0.6 - 0.7 (PE/EA = 10/1; I_2 & PMA);

¹**H NMR** (400 MHz, CDCl₃) δ 8.01 – 7.94 (m, 2H), 6.93 – 6.86 (m, 2H), 4.04 (qt, J = 9.4, 6.3 Hz, 2H), 3.88 (s, 3H), 1.85 (tdd, J = 13.4, 9.2, 6.1 Hz, 2H), 1.68 – 1.61 (m, 1H), 1.00 (dd, J = 15.1, 5.5 Hz, 4H), 0.77 – 0.69 (m, 1H), 0.17 (s, 27H); ¹³**C NMR** (101 MHz, CDCl₃) δ 167.07, 163.08, 131.70, 122.48, 114.18, 66.48, 51.95, 39.65, 29.80, 23.14, 16.72, 1.48. **IR** (ATR) 2952, 1722, 1279, 1251, 1168, 1108, 770, 623 cm⁻¹. **HRMS (ESI) m/z**: [M+Na]⁺ calcd for C₂₂H₄₄NaO₃Si₄: 491.2260; found: 491.2259.

4-(1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilan-2-yl)butyl benzoate (2k)



84.6 mg, 100%, colorless oil; Rf = 0.6 – 0.7 (PE/EA = 20:1; UV & PMA);

¹**H NMR** (400 MHz, CDCl₃) δ 8.07 – 8.01 (m, 2H), 7.58 – 7.50 (m, 1H), 7.46 – 7.39 (m, 2H), 4.34 (t, *J* = 6.5 Hz, 2H), 1.81 (p, *J* = 6.8 Hz, 2H), 1.57 (dtd, *J* = 11.6, 9.0, 8.6, 6.2 Hz, 2H), 0.91 – 0.78 (m, 2H), 0.16 (s, 27H); ¹³**C NMR** (101 MHz, CDCl₃) δ 166.76, 132.91, 130.62, 129.68, 128.41, 64.60, 33.11, 25.79, 7.49, 1.27. **IR** (ATR) 2945, 2893, 1722, 1272, 1175, 709, 623 cm⁻¹. **HRMS** (**APCI**) **m/z**: [M+H]⁺ calcd for C₂₀H₄₁O₂Si₄: 425.2178; found: 425.2182.



80.8 mg, 95%, colorless oil; Rf (PE) = 0.5 - 0.6 (PE; UV & I₂ & PMA);

¹**H NMR** (400 MHz, CDCl₃) δ 7.32 – 7.26 (m, 2H), 6.97 – 6.88 (m, 3H), 3.96 (t, J = 6.5 Hz, 2H), 1.80 (dt, J = 8.5, 6.2 Hz, 2H), 1.55 – 1.42 (m, 4H), 0.89 – 0.76 (m, 2H), 0.18 (d, J = 1.4 Hz, 27H); ¹³**C NMR** (101 MHz, CDCl₃) δ 159.27, 129.54, 120.61, 114.63, 68.01, 30.74, 29.23, 29.08, 7.72, 1.34. **IR** (ATR) 2945.71, 1242, 1039, 749, 622 cm⁻¹. **HRMS (APCI) m/z**: [M+H]⁺ calcd for C₂₀H₄₃OSi₄: 411.2385; found: 411.2390.

5-(1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilan-2-yl)pentyl benzenesulfonate (2m)



61.3 mg, 65%, colorless oil; Rf = 0.4 - 0.5 (PE/EA = 10.1; UV & PMA);

¹**H** NMR (400 MHz, CDCl₃) δ 7.94 – 7.87 (m, 2H), 7.68 – 7.62 (m, 1H), 7.59 – 7.51 (m, 2H), 4.04 (t, J = 6.5 Hz, 2H), 1.69 – 1.58 (m, 2H), 1.38 – 1.29 (m, 4H), 0.76 – 0.63 (m, 2H), 0.13 (s, 27H); ¹³**C** NMR (101 MHz, CDCl₃) δ 136.44, 133.78, 129.34, 127.97, 71.05, 29.88, 28.77, 28.57, 7.52, 1.27. **IR** (ATR) 2948, 1364, 1186, 936, 622 cm⁻¹. **HRMS (APCI) m/z**: [M+H]⁺ calcd for C₂₀H₄₃O₃SSi₄: 475.2004; found: 475.2003.

8-(1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilan-2-yl)-2,6-dimethyloctan-2-ol (2n)



41.2 mg, 47%, colorless oil; Rf = 0.6 - 0.7 (PE/EA = 5:1; I₂ & PMA);

¹**H NMR** (400 MHz, CDCl₃) δ 1.47 – 1.24 (m, 9H), 1.21 (s, 6H), 0.86 (d, *J* = 6.3 Hz, 3H), 0.82 – 0.64 (m, 2H), 0.15 (s, 27H); ¹³**C NMR** (101 MHz, CDCl₃) δ 71.25, 44.45, 37.04, 36.52, 36.47, 29.40, 29.33, 22.07, 19.32, 4.50, 1.34. **IR** (ATR) 3359, 2948, 1376, 1244, 622 cm⁻¹. **HRMS** (**APCI**) **m/z**: [M+Na]⁺ calcd for C₁₉H₄₈NaOSi₄: 427.2674; found: 427.2673.

2-dodecyl-1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilane (20)

(TMS)₃Si

75.4 mg, 93%, colorless oil; Rf = 0.9 – 1.0 (PE; PMA);

¹**H NMR** (400 MHz, CDCl₃) δ 1.27 (s, 20H), 0.92 – 0.86 (m, 3H), 0.79 – 0.72 (m, 2H), 0.16 (s, 27H); ¹³**C NMR** (101 MHz, CDCl₃) δ 34.44, 32.10, 29.86, 29.84, 29.82, 29.77, 29.52, 29.40, 29.37, 22.86, 14.28, 7.72, 1.33. **IR** (ATR) 2922, 2853, 623 cm⁻¹. **GC–MS m/z**: 416 M⁺, 247 (TMS)₃Si⁺, 169 (M-Si(TMS)₃)⁺.

1,1,1,3,3,3-hexamethyl-2-(2-(phenylthio)ethyl)-2-(trimethylsilyl)trisilane (2p)



90.6 mg, 93%, colorless oil; Rf = 0.7 – 0.8 (PE/EA = 1:1; PMA);

¹**H** NMR (400 MHz, CDCl₃) δ 2.35 (t, *J* = 7.5 Hz, 2H), 1.63 (p, *J* = 7.4 Hz, 2H), 1.38 – 1.23 (m, 14H), 0.80 – 0.70 (m, 2H), 0.15 (s, 27H); ¹³**C** NMR (101 MHz, CDCl₃) δ 180.46, 34.39, 34.23, 29.67, 29.57, 29.40, 29.38, 29.30, 29.22, 24.82, 7.70, 1.33. **IR** (ATR) 2923, 2853, 1709, 1243, 622 cm⁻¹. **HRMS (APCI) m/z**: [M-H]⁻ calcd for C₂₀H₄₇O₂Si₄: 431.2659; found: 431.2658.

oxetan-3-yl 11-(1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilan-2-yl)undecanoate (2q)



96.9 mg, 100%, colorless oil; Rf = 0.6 - 0.7 (PE/EA = 5:1; I_2 & PMA);

¹**H NMR** (400 MHz, CDCl₃) δ 5.42 (tt, J = 6.4, 5.3 Hz, 1H), 4.88 (ddd, J = 7.5, 6.4, 1.0 Hz, 2H), 4.62 (ddd, J = 7.5, 5.3, 1.0 Hz, 2H), 2.34 (t, J = 7.5 Hz, 2H), 1.38 – 1.19 (m, 14H), 0.80 – 0.64 (m, 2H), 0.15 (s, 27H); ¹³**C NMR** (101 MHz, CDCl₃) δ 173.27, 77.78, 67.81, 34.38, 34.11, 29.66, 29.56, 29.37, 29.29, 29.23, 24.94, 7.70, 1.31. **IR** (ATR) 2924, 2854, 1742, 1167, 623 cm⁻¹. **HRMS** (APCI) **m/z**: [M+H]⁺ calcd for C₂₃H₅₃O₃Si₄: 489.3066; found: 489.3071.

2-methoxyphenyl 2-methoxyphenyl 11-(1,1,1,3,3,3-hexamethyl-2- (trimethylsilyl)trisilan-2-yl)undecanoate (2r)



93.9 mg, 88%, colorless oil; Rf = 0.4 - 0.5 (PE/EA = 10:1; UV & I₂ & PMA); ¹H NMR (400 MHz, CDCl₃) δ 7.19 (ddd, J = 8.2, 7.4, 1.7 Hz, 1H), 7.02 (dd, J = 7.8, 1.7 Hz, 1H), 6.99 – 6.90 (m, 2H), 3.82 (s, 3H), 2.58 (t, J = 7.5 Hz, 2H), 1.77 (p, J = 7.4 Hz, 2H), 1.44 – 1.22 (m, 14H), 0.80 – 0.73 (m, 2H), 0.16 (d, J = 1.1 Hz, 27H); ¹³C NMR (101 MHz, CDCl₃) δ 172.06, 151.32, 140.03, 126.88, 122.99, 120.89, 112.54, 55.94, 34.41, 34.21, 29.71, 29.65, 29.45, 29.39, 29.33, 29.23, 25.19, 7.70, 1.32. IR (ATR) 2924, 2853, 1765, 1246, 1197, 623 cm⁻¹. HRMS (APCI) m/z: [M+H]⁺ calcd for C₂₇H₅₅O₃Si₄: 539.3223; found: 539.3224.

methyl 4-((11-(1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilan-2yl)undecanoyl)oxy)-3-methoxybenzoate (2s)



118.5 mg, 97%, colorless oil; Rf = 0.6 – 0.7 (PE/EA = 5:1; UV & I₂ & PMA); ¹H NMR (400 MHz, CDCl₃) δ 7.68 – 7.62 (m, 2H), 7.08 (d, *J* = 8.0 Hz, 1H), 3.91 (s, 3H), 3.87 (s, 3H), 2.58 (t, *J* = 7.5 Hz, 2H), 1.76 (p, *J* = 7.4 Hz, 2H), 1.45 – 1.25 (m, 14H), 0.80 – 0.72 (m, 2H), 0.15 (s, 27H); ¹³C NMR (101 MHz, CDCl₃) δ 171.48, 166.53, 151.23, 143.91, 128.81, 122.93, 122.74, 113.52, 56.14, 52.37, 34.38, 34.14, 29.67, 29.62, 29.40, 29.36, 29.30, 29.17, 25.08, 7.68, 1.30. **IR** (ATR) 2924, 2853, 1769, 1725, 1243, 1198, 623 cm⁻¹. **HRMS** (**APCI**) **m/z**: [M+H]⁺ calcd for C₂₉H₅₇O₅Si₄: 597.3278; found: 597.3280.

N-(2-(1H-indol-3-yl)ethyl)-11-(1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilan-2-yl)undecanamide (2t)



61.5 mg, 53%, colorless oil; Rf = 0.6- 0.7 (PE/EA = 1:1; UV & I₂ & PMA); ¹H NMR (400 MHz, CDCl₃) δ 8.36 (s, 1H), 7.61 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.42 – 7.34 (m, 1H), 7.21 (ddd, *J* = 8.2, 7.0, 1.2 Hz, 1H), 7.13 (ddd, *J* = 8.0, 7.0, 1.1 Hz, 1H), 7.01 (d, *J* = 2.4 Hz, 1H), 5.58 (d, *J* = 6.8 Hz, 1H), 3.61 (q, *J* = 6.5 Hz, 2H), 2.98 (t, *J* = 6.7 Hz, 2H), 2.10 (t, *J* = 7.7 Hz, 2H), 1.58 (t, *J* = 7.4 Hz, 2H), 1.39 – 1.23 (m, 14H), 0.79 – 0.72 (m, 2H), 0.19 – 0.13 (m, 27H); ¹³C NMR (101 MHz, CDCl₃) δ 173.42, 136.57, 127.50, 122.28, 122.19, 119.56, 118.82, 113.10, 113.07, 111.43, 39.85, 37.03, 34.41, 29.71, 29.63, 29.51, 29.45, 29.38, 29.32, 25.89, 25.49, 7.69, 1.32. **IR** (ATR) 3287, 2923, 2853, 1646, 1457, 1099, 741, 623 cm⁻¹. **HRMS (APCI) m/z**: [M+H]⁺ calcd for C₃₀H₅₉N₂OSi₄: 575.3699; found: 575.3704.

11-(1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilan-2-yl)-*N*-phenylundecanamide (2u)



99.4 mg, 98%, colorless oil; Rf = 0.5 - 0.6 (PE/EA = 5:1; UV & I₂ & PMA);

¹**H NMR** (400 MHz, CDCl₃) δ 7.55 – 7.49 (m, 2H), 7.30 (t, *J* = 7.7 Hz, 2H), 7.08 (t, *J* = 7.4 Hz, 1H), 2.34 (t, *J* = 7.6 Hz, 2H), 1.71 (q, *J* = 7.3 Hz, 2H), 1.37 – 1.25 (m, 14H), 0.78 – 0.72 (m, 2H), 0.16 (s, 27H); ¹³**C NMR** (101 MHz, CDCl₃) δ 171.72, 138.15, 129.07, 124.26, 119.98, 37.95, 34.39, 29.69, 29.62, 29.54, 29.43, 29.37, 29.30, 25.80, 7.69, 1.31. **IR** (ATR) 3299, 2924, 2853, 1661, 751, 623 cm⁻¹. **HRMS (APCI)**: [M+H]⁺ calcd for C₂₆H₅₄NOSi₄: 508.3277; found: 508.3279.

2-(2-(7-oxabicyclo[4.1.0]heptan-3-yl)ethyl)-1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilane (2v)



59.1 mg, 78%, colorless oil; Rf = 0.5 - 0.6 (PE/EA = 50:1; I_2 & PMA);

¹**H NMR** (400 MHz, CDCl₃) δ 3.18 – 3.10 (m, 2H), 2.16 (dddt, J = 17.6, 14.7, 2.9, 1.7 Hz, 1H), 2.10 – 1.93 (m, 1H), 1.84 – 1.64 (m, 1H), 1.45 – 1.31 (m, 2H), 1.29 – 1.22 (m, 2H), 1.16 – 1.01 (m, 1H), 0.87 (dtd, J = 13.1, 11.1, 6.6 Hz, 1H), 0.75 – 0.67 (m, 2H), 0.14 (d, J = 1.1 Hz, 27H); ¹³**C NMR** (101 MHz, CDCl₃) δ 52.09, 51.59, 50.82, 50.77, 35.09, 34.98, 34.59, 31.99, 30.34, 29.14, 25.65, 24.19, 22.81, 22.47, 3.31, 3.07, -0.00. **IR** (ATR) 3947, 1438, 1244, 831, 623 cm⁻¹. **GC–MS** m/z: 372 M⁺, 247 (TMS)₃Si⁺, 125 (M-Si(TMS)₃)⁺.

tert-butyl 4-(2-(1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilan-2-yl)ethyl)piperidine-1-carboxylate (2w)



85.8 mg, 94%, colorless oil; Rf = 0.6 - 0.7 (PE/EA = 10:1; I₂ & PMA);

¹**H NMR** (400 MHz, CDCl₃) δ 4.22 – 3.94 (m, 2H), 2.65 (t, J = 12.8 Hz, 2H), 1.71 – 1.59 (m, 2H), 1.44 (s, 9H), 1.36 – 1.24 (m, 3H), 1.10 – 0.96 (m, 2H), 0.80 – 0.68 (m, 2H), 0.14 (d, J = 1.0 Hz, 27H); ¹³**C NMR** (101 MHz, CDCl₃) δ 154.99, 79.25, 44.19, 39.75, 36.15, 31.94, 28.61, 4.43, 1.30. IR (ATR) 2984, 1696, 1420, 1241, 656, 623 cm⁻¹. **HRMS (ESI)**: [M+H]⁺ calcd for C₂₁H₅₀NO₂Si₄: 460.2913; found: 460.2915.

1,1,1,3,3,3-hexamethyl-2-((4-phenylcyclohexyl)methyl)-2-(trimethylsilyl)trisilane (2x)



50.3 mg, 60%, colorless oil; Rf = 0.9 - 1.0 (PE; I_2 & PMA);

¹**H** NMR (400 MHz, CDCl₃) δ 7.33 – 7.27 (m, 2H), 7.25 – 7.16 (m, 3H), 2.48 (tt, *J* = 12.2, 3.2 Hz, 1H), 2.00 – 1.86 (m, 4H), 1.47 (qd, *J* = 13.8, 12.9, 3.9 Hz, 2H), 1.41 –

1.32 (m, 1H), 1.19 – 1.04 (m, 2H), 0.84 (d, J = 6.8 Hz, 2H), 0.21 (s, 27H); ¹³C NMR (101 MHz, CDCl₃) δ 147.74, 128.41, 126.98, 125.97, 44.21, 37.52, 37.35, 34.71, 16.41, 1.53. **IR** (ATR) 2920, 1447, 695, 623 cm⁻¹. **GC–MS m/z**: 420 M⁺, 247 (TMS)₃Si⁺, 173 (M-Si(TMS)₃)⁺.

2-benzamido-2-(3-methyl-2-(4,4,4-trifluorobutyl)phenyl)acetic acid (2y)



57.5 mg, 69%, colorless oil; Rf = 0.9 - 1.0 (PE; I₂ & PMA);

¹**H NMR** (400 MHz, CDCl₃) δ 1.82 – 1.70 (m, 4H), 1.32 – 1.20 (m, 8H), 1.15 (tt, J = 7.3, 3.8 Hz, 3H), 0.90 – 0.85 (m, 6H), 0.75 (d, J = 6.8 Hz, 2H), 0.16 (s, 27H); ¹³**C NMR** (101 MHz, CDCl₃) δ 38.03, 37.53, 37.50, 37.16, 33.80, 32.40, 26.87, 22.88, 16.44, 14.28, 1.52. **IR** (ATR) 2918, 1446, 623 cm⁻¹. **GC–MS m/z**: 414 M⁺, 247 (TMS)₃Si⁺, 153 (M-CH₂-(TMS)₃Si)⁺.

2-(2-butoxyethyl)-1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilane (2z) (TMS)₃Si

69.2 mg, 95%, colorless oil; Rf = 0.5 - 0.6 (PE/EA = 30:1; I_2 & anisaldehyde & PMA);

¹**H NMR** (400 MHz, CDCl₃) δ 3.49 – 3.43 (m, 2H), 3.40 (t, *J* = 6.8 Hz, 2H), 1.56 (ddd, *J* = 7.7, 6.2, 1.3 Hz, 2H), 1.42 – 1.34 (m, 2H), 1.24 – 1.16 (m, 2H), 0.92 (t, *J* = 7.4 Hz, 3H), 0.16 (s, 27H); ¹³**C NMR** (101 MHz, CDCl₃) δ 70.90, 70.36, 32.09, 19.55, 14.10, 9.47, 1.23. IR (ATR) 2951, 1243, 1099, 622 cm⁻¹. **HRMS (APCI) m/z**: [M+H]⁺ calcd for C₁₅H₄₁OSi₄: 349.2229; found: 349.2226.

2-(1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilan-2-yl)ethyl benzoate (2aa)



79.9 mg, 95%, colorless oil; Rf = 0.7 - 0.8 (PE/EA = 20:1; UV & I₂ & PMA); ¹H NMR (400 MHz, CDCl₃) δ 8.09 - 8.02 (m, 2H), 7.57 - 7.51 (m, 1H), 7.46 - 7.40 (m, 2H), 4.43 - 4.35 (m, 2H), 1.40 - 1.33 (m, 2H), 0.22 (s, 27H); ¹³C NMR (101 MHz, CDCl₃) δ 166.71, 132.88, 130.86, 129.68, 128.44, 65.55, 9.10, 1.21. **IR** (ATR) 2950, 2894, 1717, 1174, 1101, 623 cm⁻¹. **GC–MS m/z**: 396 M⁺, 247 (TMS)₃Si⁺, 149 (M-Si(TMS)₃)⁺, 105 (PhCO)⁺.

1,1,1,3,3,3-hexamethyl-2-(2-(phenylthio)ethyl)-2-(trimethylsilyl)trisilane (2ab)



74.5 mg, 94%, colorless oil; Rf = 0.9 - 1.0 (PE; I_2 & PMA);

¹**H NMR** (400 MHz, CDCl₃) δ 7.29 – 7.21 (m, 4H), 7.13 (ddt, J = 6.6, 5.7, 2.4 Hz, 1H), 3.00 – 2.92 (m, 2H), 1.19 – 1.11 (m, 2H), 0.13 (d, J = 1.0 Hz, 27H); ¹³**C NMR** (101 MHz, CDCl₃) δ 137.00, 129.31, 129.01, 125.97, 33.90, 8.63, 1.29. **IR** (ATR) 2953, 2924, 1083, 691, 623 cm⁻¹. **HRMS (ESI)** m/z: [M+H]⁺ calcd for C₁₇H₃₇SSi₄: 385.1688; found:385.1684.

4-(4-(benzamido(carboxy)methyl)-[1,1'-biphenyl]-3-yl)butanoic acid (2ac)



43.3 mg, 62%, colorless oil; Rf = 0.9-1.0 (PE; I₂ & PMA);

¹**H NMR** (400 MHz, CDCl₃) δ 7.33 – 7.26 (m, 2H), 7.22 – 7.14 (m, 3H), 2.65 (t, J = 7.6 Hz, 2H), 1.78 – 1.67 (m, 2H), 0.88 – 0.80 (m, 2H), 0.16 (s, 27H); ¹³**C NMR** (101 MHz, CDCl₃) δ 142.53, 128.57, 128.39, 125.78, 40.64, 31.07, 7.59, 1.31. IR (ATR) 2951, 1037, 623 cm⁻¹. **GC–MS m/z**: 366 M⁺, 247 (TMS)₃Si⁺, 119 (M-Si(TMS)₃)⁺.

5-(3-(1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilan-2-yl)propyl)-2methoxyphenol (2ad)



59.4 mg, 72%, colorless oil; Rf = 0.4 - 0.5 (PE/EA = 10:1; UV & I₂ & anisaldehyde & PMA);

¹**H NMR** (400 MHz, CDCl₃) δ 6.86 – 6.81 (m, 1H), 6.66 (d, *J* = 6.8 Hz, 2H), 5.47 (s, 1H), 3.87 (s, 3H), 2.57 (t, *J* = 7.5 Hz, 2H), 1.76 – 1.63 (m, 2H), 0.86 – 0.75 (m, 2H),

0.15 (s, 27H); ¹³C NMR (101 MHz, CDCl₃) δ 146.41, 143.67, 134.50, 121.14, 114.25, 111.09, 55.96, 40.19, 31.30, 7.41, 1.31. **IR** (ATR) 3556, 2949, 1265, 1123, 1036, 623 cm⁻¹. **HRMS (APCI) m/z**: [M+H]⁺ calcd for C₁₉H₄₁O₂Si₄: 413.2178; found: 413.2177.

4-(1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilan-2-yl)-*N*-phenylbutanamide (2ae)



This reaction was conducted at 110 °C; 64.9 mg, 79%, white solid; Rf = 0.4 - 0.5 (PE/EA = 10:1; UV);

¹**H NMR** (400 MHz, CDCl₃) δ 7.55 – 7.48 (m, 2H), 7.37 – 7.24 (m, 3H), 7.09 (t, J = 7.4 Hz, 1H), 2.38 (t, J = 7.2 Hz, 2H), 1.82 (dq, J = 11.2, 7.4 Hz, 2H), 0.89 – 0.79 (m, 2H), 0.17 (s, 27H); ¹³**C NMR** (101 MHz, CDCl₃) δ 171.00, 138.10, 129.10, 124.28, 120.00, 42.11, 25.37, 7.86, 1.51, 1.30, 1.07. **IR** (ATR) 3288, 2950, 2893, 1659, 1442, 1107, 689, 622 cm⁻¹. **HRMS (APCI) m/z**: [M+H]⁺ calcd for C₁₉H₄₀NOSi₄: 410.2181; found: 410.2181. **m.p.**: 156.9-157.9 °C.

4-((1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilan-2-yl)methyl)-3,4dihydroquinolin-2(1H)-one (2ae')



This reaction was conducted at 110 °C; 16.9 mg, 21%, white solid; Rf = 0.2 - 0.3 (PE/EA = 10:1; UV);

¹**H NMR** (400 MHz, CDCl₃) δ 8.25 (d, J = 64.1 Hz, 1H), 7.17 (dtd, J = 8.2, 4.1, 1.5 Hz, 2H), 7.02 (td, J = 7.4, 1.2 Hz, 1H), 6.77 (ddd, J = 8.0, 5.2, 1.3 Hz, 1H), 3.05 (dq, J = 10.4, 5.2 Hz, 1H), 2.79 – 2.71 (m, 1H), 2.56 (dd, J = 16.1, 4.7 Hz, 1H), 1.23 – 1.15 (m, 2H), 0.22 (s, 27H); ¹³**C NMR** (101 MHz, CDCl₃) δ 170.98, 135.98, 130.69, 127.56, 126.90, 123.54, 115.89, 37.70, 36.10, 14.37, 1.49. **IR** (ATR) 2951, 168, 1595, 1245, 834, 623 cm⁻¹. **HRMS (APCI) m/z**: [M+H]⁺ calcd for C₁₉H₃₈NOSi₄: 408.2025; found: 408.2024. **m.p.**: 141.9-142.9 °C.

phenyl 3-(1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilan-2-yl)propanoate (2af)



75.1 mg, 91%, colorless oil; Rf = 0.4 - 0.5 (PE/EA = 30:1; UV);

¹**H NMR** (400 MHz, CDCl₃) δ 7.42 – 7.34 (m, 2H), 7.26 – 7.19 (m, 1H), 7.15 – 7.06 (m, 2H), 2.63 – 2.51 (m, 2H), 1.27 – 1.20 (m, 2H), 0.22 (d, J = 1.0 Hz, 27H); ¹³**C NMR** (101 MHz, CDCl₃) δ 173.24, 151.03, 129.52, 125.84, 121.70, 33.56, 3.04, 1.23. **IR** (ATR) 2949, 2893, 1761, 1190, 1030, 622 cm⁻¹. **HRMS** (**APCI**): [M+Na]⁺ calcd for C₁₈H₃₆NaO₂Si₄: 419.1685; found: 419.1680.

Si(TMS)₃

91.0 mg, 100%, colorless oil; Rf = 0.5 - 0.6 (PE/EA = 10:1; I_2 & anisaldehyde & PMA);

¹**H** NMR (400 MHz, CDCl₃) δ 4.92 – 4.88 (m, 1H), 2.38 – 2.29 (m, 4H), 2.00 (t, J = 7.0 Hz, 4H), 1.87 – 1.81 (m, 4H), 1.79 – 1.71 (m, 4H), 1.61 – 1.50 (m, 2H), 1.17 – 1.08 (m, 2H), 0.18 (d, J = 1.2 Hz, 27H); ¹³**C** NMR (101 MHz, CDCl₃) δ 174.26, 76.96, 37.56, 36.48, 36.46, 33.96, 31.98, 31.96, 31.93, 27.40, 27.15, 3.33, 1.19. **IR** (ATR) 2909, 2856, 1731, 1199, 623 cm⁻¹. **HRMS (APCI) m/z**: [M+H]⁺ calcd for C₂₂H₄₇O₂Si₄: 455.2648; found: 455.2650.

3-(1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilan-2-yl)-*N***-phenylpropanamide** (2ah)

NH Si(TMS)₃

58.5 mg, 68%, white solid; Rf = 0.8 - 0.9 (PE/EA = 5:1; UV);

¹**H NMR** (400 MHz, CDCl₃) δ 7.53 (d, *J* = 8.0 Hz, 2H), 7.32 (t, *J* = 7.9 Hz, 2H), 7.17 – 7.05 (m, 2H), 2.46 – 2.33 (m, 2H), 1.26 – 1.15 (m, 2H), 0.20 (s, 27H); ¹³**C NMR** (101 MHz, CDCl₃) δ 172.11, 138.11, 129.15, 124.32, 119.83, 36.84, 3.48, 1.27. **IR** (ATR) 3293, 2951, 1660, 1603, 750, 623 cm⁻¹. **HRMS** (**APCI**) **m/z**: [M+H]⁺ calcd for

C₁₈H₃₈NOSi₄: 396.2025; found: 396.2028. **m.p.**: 195.4-196.3 °C.

1,1,1,3,3,3-hexamethyl-2-phenethyl-2-(trimethylsilyl)trisilane (2ai)

Si(TMS)3

24.4 mg, 35%, colorless oil; Rf = 0.9 - 1.0 (PE; I₂ & PMA);

¹**H NMR** (400 MHz, CDCl₃) δ 7.35 – 7.27 (m, 2H), 7.20 (d, J = 7.5 Hz, 3H), 2.74 – 2.66 (m, 2H), 1.18 – 1.10 (m, 2H), 0.23 (s, 27H); ¹³**C NMR** (101 MHz, CDCl₃) δ 145.90, 128.58, 127.74, 125.84, 35.65, 10.75, 1.34. **IR** (ATR) 2949, 2892, 1065, 622 cm⁻¹. **GC–MS m/z**: 352 M⁺, 247 (TMS)₃Si⁺, 105 (M-Si(TMS)₃)⁺.

1,6-bis(1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilan-2-yl)hexane (2aj)

(TMS)₂Si Si(TMS)₃

106.0 mg, 91%, white solid; Rf = 0.9 - 1.0 (PE; PMA);

¹**H NMR** (400 MHz, CDCl₃) δ 1.43 – 1.30 (m, 8H), 0.81 – 0.74 (m, 4H), 0.16 (s, 54H); ¹³**C NMR** (101 MHz, CDCl₃) δ 34.23, 29.49, 7.92, 1.40. **IR** (ATR) 2950, 622 cm⁻¹. **GC–MS m/z**: 578 M⁺, 247 (TMS)₃Si⁺. **m.p.**: 175.5-176.5 °C.

(8*R*,9*S*,13*S*,14*S*)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6Hcyclopenta[a]phenanthren-3-yl 7-(1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilan-2-yl)heptanoate (2ak)



117.0 mg, 95%, colorless oil; Rf = 0.7 - 0.8 (PE/EA = 1:1; UV & I₂ & anisaldehyde & PMA);

¹**H NMR** (400 MHz, CDCl₃) δ 7.30 – 7.24 (m, 1H), 6.87 – 6.80 (m, 2H), 2.91 (dd, J = 8.3, 3.6 Hz, 2H), 2.57 – 2.46 (m, 3H), 2.43 – 2.38 (m, 1H), 2.31 – 2.24 (m, 1H), 2.20 – 2.11 (m, 1H), 2.09 – 1.94 (m, 3H), 1.74 (p, J = 7.1 Hz, 2H), 1.67 – 1.59 (m, 2H), 1.58 – 1.50 (m, 3H), 1.48 (d, J = 4.3 Hz, 1H), 1.45 – 1.38 (m, 6H), 0.91 (s, 3H), 0.82 – 0.74 (m, 2H), 0.16 (s, 27H); ¹³**C NMR** (101 MHz, CDCl₃) δ 220.92, 172.72, 148.78,

138.08, 137.38, 126.50, 121.73, 118.91, 50.57, 48.07, 44.28, 38.14, 35.98, 34.53, 34.01, 31.68, 29.53, 29.24, 28.83, 26.48, 25.88, 25.13, 21.71, 13.95, 7.69, 1.31. **IR** (ATR) 2956, 2927, 2858, 1733, 1273, 1073, 623 cm⁻¹. **HRMS (APCI) m/z**: $[M+H]^+$ calcd for C₃₄H₆₁O₃Si₄: 629.3692; found: 629.3696.

(3*S*,8*S*,9*S*,10*R*,13*R*,14*S*,17*R*)-10,13-dimethyl-17-((*R*)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl 5-(1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilan-2-yl)pentanoate (2al)



139.0 mg, 97%, colorless oil; Rf = 0.9 - 1.0 (PE/EA = 10:1; I_2 & anisaldehyde & PMA);

¹**H NMR** (400 MHz, CDCl₃) δ 5.37 (tt, *J* = 3.9, 2.5 Hz, 1H), 4.60 (dtd, *J* = 14.3, 7.3, 4.9 Hz, 1H), 2.33 – 2.24 (m, 4H), 1.99 (ddt, *J* = 20.5, 17.6, 4.2 Hz, 2H), 1.84 (dtd, *J* = 12.2, 6.1, 3.5 Hz, 3H), 1.69 – 1.24 (m, 20H), 1.17 – 1.08 (m, 6H), 1.02 (d, *J* = 1.8 Hz, 5H), 0.92 (s, 3H), 0.88 – 0.84 (m, 9H), 0.79 – 0.75 (m, 2H), 0.68 (s, 3H), 0.15 (s, 27H); ¹³**C NMR** (101 MHz, CDCl₃) δ 173.26, 139.83, 122.71, 73.85, 56.84, 56.29, 50.18, 42.46, 39.89, 39.68, 38.34, 37.16, 36.74, 36.34, 35.94, 34.47, 32.06, 32.01, 29.58, 28.90, 28.38, 28.16, 27.98, 24.43, 23.98, 22.98, 22.72, 21.18, 19.47, 18.87, 12.00, 7.47, 1.31. **IR** (ATR) 2946, 1734, 1465, 1378, 1186, 834, 623 cm⁻¹. **HRMS** (**ESI**) **m/z**: [M+Na]⁺ calcd for C₄₁H₈₀NaO₂Si₄: 739.5128; found: 739.5130.

Gram-Scale Reaction





1.0514 g, 6 mmol, 1.0 equiv.) and oxime ester (113.5 mg, 0.6 mmol, 10 mol%). The Schlenk bottle was then evacuated and back-filled with nitrogen (N₂, 99.999%) for 3 times. Then fresh-distilled anhydrous 1,4-dioxane (60 mL) and (TMS)₃SiH (4.6 mL, 15 mmol, 2.5 equiv.) was added via syringe. Then the reaction mixture was stirred at 60 °C for 48 h. After completion (monitored by TLC), the reaction mixture was cooled to room temperature and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (PE/EA = 6:1) to afford the desired product **2a** (white solid, 2.4691 g, 97% yield).

5. Tolerance of Internal Olefins.

We have evaluated several internal olefins. Unfortunately, none of them provides desired products, indicating that the reaction is sensitive to the steric properties of alkenes. Overall, our methodology mainly tolerates mono-substituted and geminal substituted olefins.



A dried Schlenk tube (10 mL) was charged with a stirring bar, alkene **1a**, the initiator **I** (18.9 mg, 0.1 mmol, 1.0 equiv.) and TEMPO (31.3 mg, 0.2 mol, 1.0 equiv.). The Schlenk tube was then evacuated and back-filled with nitrogen (N_2 , 99.999%) for 3 times. Then fresh-distilled anhydrous 1,4-dioxane (2 mL) was added via syringe.

The reaction mixture was stirred at 60 °C for 48 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The crude product was dissolved by MeOH and measured via HRMS. **HRMS** (**ESI**) $\mathbf{m/z}$: $[M+H]^+$ calcd for C₁₈H₃₇O₂Si₄: 225.1961; found: 225.1959.



A dried Schlenk tube (10 mL) was charged with a stirring bar, alkene **1a** (35.0 mg, 0.2 mmol, 1.0 equiv.) and initiator **I** (7.6 mg, 0.04 mmol, 20 mol%). The Schlenk tube was then evacuated and back-filled with nitrogen (N₂, 99.999%) for 3 times. The fresh-distilled anhydrous 1,4-dioxane (2 mL) (via syringe) and Ph₂SiH₂ (111.8 mg, 0.6 mol, 3.0 equiv.) were added in sequence. The reaction mixture was refluxed for 15 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by column chromatography (EA/PE = 1/5) to obtain **4a** (53.7 mg, 75%, colorless oil, $R_f = 0.4 - 0.5$ (PE/EA = 5:1, UV/PMA)). ¹**H NMR** (400 MHz, CDCl₃) δ 7.66 - 7.55 (m, 4H), 7.49 (d, *J* = 7.9 Hz, 2H), 7.45 - 7.30 (m, 8H), 7.13 (q, *J* = 8.0, 7.4 Hz, 2H), 4.89 (t, *J* = 3.7 Hz, 1H), 2.34 (t, *J* = 7.6 Hz,

2H), 1.83 (p, J = 7.5 Hz, 2H), 1.64 – 1.52 (m, 2H), 1.27 – 1.15 (m, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 171.39, 138.02, 135.23, 134.39, 129.73, 129.07, 128.15, 124.33, 120.03, 37.51, 29.07, 24.31, 12.13.



A dried Schlenk tube (10 mL) was charged with a stirring bar, alkene **1a** (35.0 mg, 0.2 mmol, 1.0 equiv.) and the initiator **I** (7.6 mg, 0.04 mmol, 20 mol%). The Schlenk tube was then evacuated and back-filled with nitrogen (N₂, 99.999%) for 3 times. The fresh-distilled anhydrous 1,4-dioxane (2 mL) (via syringe) and Ph₂SiD₂ (111.8 mg, 0.6 mol, 3.0 equiv.) were added in sequence. The reaction mixture was refluxed for 36 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by column chromatography (EA/PE = 1/5) to obtain **4a**-*d* (47.2 mg, 66%, colorless oil, $R_f = 0.4 - 0.5$ (PE/EA = 5:1, UV/PMA)).

¹**H NMR** (400 MHz, CDCl₃) δ 7.60 – 7.53 (m, 2H), 7.48 (d, J = 8.0 Hz, 2H), 7.43 – 7.24 (m, 10H), 7.10 (t, J = 7.4 Hz, 1H), 2.31 (t, J = 7.6 Hz, 2H), 1.80 (p, J = 7.4 Hz, 2H), 1.55 (p, J = 8.0 Hz, 1H), 1.19 (t, J = 8.0 Hz, 2H); ¹³**C NMR** (101 MHz, CDCl₃) δ 174.56, 139.82, 136.08, 135.56, 135.47, 135.37, 135.32, 131.05, 130.66, 129.75, 129.16, 129.08, 128.98, 128.72, 125.14, 121.34, 37.55, 30.25, 30.15, 25.16, 12.67. 7.

7. The Rational for Both Carbon Radical and Benzoate Radical Interact with Silane via Hydrogen Abstract to Achieve Silyl Radical.

The BDE (Bond Dissociation Energy) of PhCOO-H and H-CH₂CN are 111 and 95 kcal/mol (BDE of H-CH₂CH₂CH₂CR) is not found in iBonD data base: <u>http://ibond.nankai.edu.cn/</u>) respectively which are much higher than (TTMS)Si-H(79 kcal/mol). After homolysis of oxime ester, both generated alkyl carbon radical and benzoate radical could feasibly abstract hydrogen radical from (TTMS)SiH to provide

more thermodynamically stable (TTMS)Si.

8. The Rational for Selecting (TMS)₃SiH as Silane for Condition Optimization.

(TMS)₃SiH has a lower Si-H bond strength of 79 kcal/mol compared with other silanes (PhSiH₃, 90 kcal/mol; Ph₂SiH₂, 86 kcal/mol; Et₃SiH, 95 kcal/mol). So, a hydrogen abstract between (TMS)₃SiH and alkyl carbon radical would be proceeded more feasible than other silanes under mild reaction temperature.

9. The Rational for Excellent Chemoselectivity of γ-Cyanoalkyl Radical with Silane and Alkene.

According to the reported references²⁻⁴, the rate constant for the addition of primary carbon radical to olefin is the range $0.6-1.2 \times 10^5 \,\text{M}^{-1}\text{s}^{-1}$ (scheme S1, path a). Meanwhile the rate constant for abstraction of (TTMS)Si-H from primary carbon radical is $3.8 \times 10^5 \,\text{M}^{-1}\text{s}^{-1}$ (scheme S1, path b). The rate constants of forming silyl radical **ii** is 3-6 times faster than generating carbon radical **i**. More importantly, the rate constant for the addition of an (TTMS)Si onto olefin is the range $5.8-9.7 \times 10^7 \,\text{M}^{-1}\text{s}^{-1}$ which is 800-1000 times faster than an alkyl radical onto an olefin. So, it is more reasonable that both carbon radical **i** (path a) and silyl radical **ii** (path b) may exist in this reaction where path b is dominated. Overall, the distinct rate constant that formation of **i**, **ii** and **iv** illustrates the good chemoselectivity in this reaction.



Scheme S1

10. Reference

1. Zhao, B. L. and Shi, Z. Z. Copper-Catalyzed Intermolecular Heck-Like Coupling of Cyclobutanone Oximes Initiated by Selective C-C Bond Cleavage. *Angew Chem Int Ed*, **2017**, *56*, 12727-12731.

2. C. Chatgilialoglu, Organosilanes as radical-based reducing agents in synthesis. *Acc. Chem. Res.* **1992**, 25, 188-194.

3. L. J. Johnston, J. C. Scaiano and K. U. Ingold, Kinetics of cyclopropyl radical reactions. 1. Absolute rate constants for some addition and abstraction reactions. *J. Am.Chem. Soc.*, **1984**, 106, 4877-4881.

4. D. V. Avila, K. U. Ingold, J. Lusztyk, W. R. Dolbier and H. Q. Pan, Absolute Rate Constants for Radical Additions to Alkenes in Solution. The Synergistic Effect of Perfluorination on the Reactivities of n-Alkyl Radicals.*J. Org. Chem.* **1996**, 61, 2027 - 2030.





0.0

¹³C NMR spectrum of compound **1e** (101 MHz, CDCl₃)


¹H NMR spectrum of compound **1j** (400 MHz, CDCl₃)









¹H NMR spectrum of compound **1q** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **1q** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **1r** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **1r** (101 MHz, CDCl₃)



 1 H NMR spectrum of compound **1s** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **1s** (101 MHz, CDCl₃)

171.46 166.52	151.20 143.87 139.26	128.80 122.91 122.72 114.29 113.50	56.14 52.37 33.89 29.17 29.17 29.11 25.05
	2 5 5	$\land \lor \lor$	







210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm)

¹H NMR spectrum of compound **1t** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **1t** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **1ag** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **1ag** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **1ak** (400 MHz, CDCl₃)





¹³C NMR spectrum of compound **1ak** (101 MHz, CDCl₃)

¹H NMR spectrum of compound **1al** (400 MHz, CDCl₃)



 ^{13}C NMR spectrum of compound 1al (101 MHz, CDCl_3)



¹H NMR spectrum of compound **VII** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **VII** (400 MHz, CDCl₃)



¹H NMR spectrum of compound VIII (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **VIII** (400 MHz, CDCl₃)



¹H NMR spectrum of compound **IX** (400 MHz, CDCl₃)





S-56



NOESY spectrum of compound VII (400 MHz, CDCl₃)

¹H NMR spectrum of compound **D₂SiPh₂** (400 MHz, CDCl₃)







210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm) ¹H NMR spectrum of compound **3a** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **3a** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2a** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2a** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2b** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2b** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2c** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2c** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2d** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2d** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2e** (400 MHz, CDCl₃)


¹³C NMR spectrum of compound **2e** (101 MHz, CDCl₃)







¹³C NMR spectrum of compound **2f** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2g** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2g** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2h** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2h** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2i** (400 MHz, CDCl₃)







¹H NMR spectrum of compound **2j** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2j** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2k** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2k** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2l** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2l** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2m** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2m** (101 MHz, CDCl₃)





¹H NMR spectrum of compound **2n** (400 MHz, CDCl₃)





¹H NMR spectrum of compound **20** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **20** (101 MHz, CDCl₃)

4	0	ဖ	4	2	\sim	2	0	\sim	ω	ω		
4		ω	ω	ω	\sim	S	4	Э	ω	2	\sim	e
4	~i	<u> </u>	с.	<u> </u>	с.	Ģ.	с.	с.	~i	4	\sim	e
ň	ò	Ň	Ň	Ň	Ň	Ň	Ň	Ň	Ň.	÷	~	÷.
۰Ľ	1			- ;	5						<u> </u>	<u> </u>



230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm)

 1 H NMR spectrum of compound **2p** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2p** (101 MHz, CDCl₃)





¹H NMR spectrum of compound **2q** (400 MHz, CDCl₃)



S-94

¹³C NMR spectrum of compound **2q** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2r** (400 MHz, CDCl₃)







¹H NMR spectrum of compound **2s** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2s** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2t** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2t** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2u** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2u** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2v** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2v** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2w** (400 MHz, CDCl₃)


¹³C NMR spectrum of compound **2w** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2x** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2x** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2y** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2y** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2z** (400 MHz, CDCl₃)







¹H NMR spectrum of compound **2aa** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2aa** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2ab** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2ab** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2ac** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2ac** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2ad** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2ad** (101 MHz, CDCl₃)





¹H NMR spectrum of compound **2ae** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2ae** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2ae'** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2ae'** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2af** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2af** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2ag** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2ag** (101 MHz, CDCl₃)



76.96	37.56 36.48 36.46 33.96 31.98 31.98 31.98 31.98 31.93 27.40 27.15	3.33 1.19
		57



¹H NMR spectrum of compound **2ah** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2ah** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2ai** (400 MHz, CDCl₃)

0 0 0 $ 0$ 0 0 $+$ $ 0$ 0 $ -$	0 - 0 0 0 0	0 U 4 4 U U	ŝ
<u>, , , , , , , , , , , , , , , , , , , </u>			Ņ
ファット・ファット・ファッ			0
			1



¹³C NMR spectrum of compound **2ai** (101 MHz, CDCl₃)







¹³C NMR spectrum of compound **2aj** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2ak** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2ak** (101 MHz, CDCl₃)



¹H NMR spectrum of compound **2al** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **2al** (101 MHz, CDCl₃)



 1 H NMR spectrum of compound **4a** (400 MHz, CDCl₃)



¹³C NMR spectrum of compound **4a** (101 MHz, CDCl₃)





S-142
¹³C NMR spectrum of compound **4a**-*d* (101 MHz, CDCl₃)



COSY spectrum of compound 4a-d (101 MHz, CDCl₃)



HMBC spectrum of compound 4a-d (101 MHz, CDCl₃)



HSQC spectrum of compound 4a-d (101 MHz, CDCl₃)

